Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the second quarter 2025 Appellus Pharmaceuticals, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Tracy Bennis, Vice President of Communications. Please go ahead. Good morning, and thank you for joining us to discuss Appellus' second quarter 2025 financial results. With me on the call are co-founder and Chief Executive Officer, Dr. Cedric Francois, Chief Financial Officer, Tim Sullivan, Chief Medical Officer, Dr. Caroline Baumel, and Executive Vice President of Commercial, David Acheson. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. Now, I'll turn the call over to Cedric. Thank you, Tracy. As many of you know, Apelis is a pioneering biopharmaceutical company with two approved C3 targeting medicines, Cyfovir and Empatheli, both with blockbuster potential and a pipeline of innovative therapies. We are focused on treating diseases with high unmet needs by targeting C3, the central protein in the complement cascade, and the only target that addresses all three activation pathways that can initiate and drive disease. E...